In idiopathic pulmonary fibrosis (IPF), the trajectory of declining lung function and clinical worsening was less drastic with the use of inhaled treprostinil (Tyvaso), the placeb ...

Bedfont® Scientific Limited, an innovative med-tech company specializing in medical breath analysis devices, welcomes the new study at University Hospital Southampton exploring whether enhanced asthma ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...

In outpatient care, RSV infections in children younger than 2 years present with distinct clinical features and greater ...

MannKind’s fair value estimate has been trimmed from US$9.61 to US$7.50, a roughly 22% cut that sets a more conservative anchor for the stock. This reset lines up with a split analyst backdrop, where ...

So thank you, everyone, for joining us in the room and online at TD Cowen's 46th Annual Healthcare Conference. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen. And it is ...

Q4 2025 revenues of $112M, +46% vs. Q4 2024Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 ...

MannKind (NASDAQ:MNKD) reported record fourth-quarter revenue and outlined key regulatory and clinical catalysts for 2026 ...

Investing.com -- MannKind Corporation (NASDAQ:MNKD) shares fell 37% Wednesday after partner United Therapeutics unveiled a soft-mist inhaler that will compete with dry powder inhalation therapies.

The resolution, aimed at reducing the incidence of tobacco and nicotine use by youth, goes to the Fargo City Commission for consideration.